Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran

[1] Ansell J(2004)The pharmacology and management of the vitamin K antagonists. The seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy Chest 126 204S-233S

[2] Hirsh J(2004)Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 401-428

[3] Poller L(2003)Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thromb Haemost 89 288-296

[4] Bussey H(2003)Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor. In young healthy male subjects Eur J Clin Pharmacol 59 35-43

[5] Jacobson A(2003)Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 1691-1698

[6] Hylek E(2005)Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial JAMA 293 681-689

[7] Büller HR(2003)Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 1703-1712

[8] Agnelli G(2001)The direct thrombin inhibitor melagatran and its oral prodrug H 376/95; intestinal absorption properties, biochemical and pharmacodynamic effects Thromb Res 101 171-181

[9] Hull RD(2000)Fixed-dose, body weight-independent subcutaneous LMW Heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis Thromb Haemost 83 652-656

[10] Hyers TM(1999)A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N Engl J Med 340 901-907

[1] Ansell J(2004)The pharmacology and management of the vitamin K antagonists. The seventh ACCP Conference of Antithrombotic and Thrombolytic Therapy Chest 126 204S-233S

[2] Hirsh J(2004)Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 401-428

[3] Poller L(2003)Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement Thromb Haemost 89 288-296

[4] Bussey H(2003)Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor. In young healthy male subjects Eur J Clin Pharmacol 59 35-43

[5] Jacobson A(2003)Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 1691-1698

[6] Hylek E(2005)Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial JAMA 293 681-689

[7] Büller HR(2003)Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement N Engl J Med 349 1703-1712

[8] Agnelli G(2001)The direct thrombin inhibitor melagatran and its oral prodrug H 376/95; intestinal absorption properties, biochemical and pharmacodynamic effects Thromb Res 101 171-181

[9] Hull RD(2000)Fixed-dose, body weight-independent subcutaneous LMW Heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis Thromb Haemost 83 652-656

[10] Hyers TM(1999)A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism N Engl J Med 340 901-907